New Data Affirms Value of Breast Cancer Index (BCI) in Identification of Early Stage ER+ Breast Cancer Patients Appropriate for Extended Endocrine Therapy (EET)

Biotheranostics, Inc. today announced new data further demonstrating the importance of BCI in clinical practice. In a study of more than 14,000 cases, the largest patient study for BCI, BCI identified 31.5% of patients with node-negative (LN-) breast cancer – those who are typically considered at lower risk for recurrence and who may not be recommended for extended endocrine therapy (EET) – as high risk of recurrence and high likelihood of benefit from an additional 5 years of therapy. Conversely, the study also identified 16% of node positive (LN+) patients who are typically considered at higher risk of recurrence and likely to be recommended extended therapy as low risk of recurrence between years 5-10 and low likelihood of benefit from extended endocrine therapy. A separate study of the BCI database stratified patients by age, and demonstrated that in patients aged 75 or older, for whom treatment considerations are often more complex, BCI identified similar rates of patients with HR+, LN–breast cancer as having high vs. low risk of late distant recurrence and high vs.  low likelihood of benefit from EET.

The studies are being presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago this week.